WCN26-6077 SUSTAINED REDUCTION OF ELEVATED INTACT PARATHYROID HORMONE CONCENTRATIONS WITH EXTENDED-RELEASE CALCIFEDIOL SLOWS CHRONIC KIDNEY DISEASE PROGRESSION IN CHINESE SECONDARY HYPERPARATHYROIDISM PATIENTS:A POST-HOC ANALYSIS

Read full text Summarise with VIRAT
Authors: Ming Fang, Yan Hao, Huijuan Mao, Hong Ren, Hongyan Tian, Haiming Li, Hongli Lin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) is a worldwide public health problem with steadily increasing incidence, prevalence and cost. By 2050, CKD is predicted to become the fifth leading age-standardized cause of death worldwide. Secondary hyperparathyroidism (SHPT) develops as CKD advances, and persistently elevated parathyroid hormone (PTH) may be nephrotoxic and associated with earlier dialysis onset. A post-hoc analysis of two Phase 3 studies conducted in the United States has shown that sustained reduction of elevated intact PTH (iPTH) of ≥30% from baseline (BL) with extended-release calcifediol (ERC) treatment was associated with slower rates of estimated glomerular filtration rate (eGFR) decline in patients with SHPT and stage 3-4 CKD.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Chronic Kidney Disease and Diabetes Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104247–104247
Publication date
25 March 2026
Language
EN